Why the study?
Does micro-axial rotational pump support during high risk percutaneous coronary intervention yield favorable in-hospital outcomes in real-world registry patients compared to clinical trial patients?
Does micro-axial rotational pump support during high risk percutaneous coronary intervention yield favorable in-hospital outcomes in real-world registry patients compared to clinical trial patients?
Answers are grounded in this paper and cite their sources.
Real-world use of micro-axial rotational pumps for high-risk PCI in the USpella registry showed favorable and consistent in-hospital outcomes compared to the PROTECT II trial cohort, despite higher baseline risk.
Cohen et al. have published the article (1), analyzing the use percutaneous left ventricular assist device (PLVAD) to support high risk percutaneous coronary intervention (HRPCI). The authors performed retrospective observational analysis of 339 patients included in the USpella registry, who were supported for HRPCI with a micro-axial rotational pump (Impella 2.5). There were patients that have met eligibility for the Impella arm of the PROTECT II trial (2). In-hospital outcomes of the USpella registry patients were compared with the results of 216 patients treated in the Impella arm of PROTECT II randomized trial. The authors concluded that despite the higher risk of registry patients, clinical outcomes appeared to be favorable and consistent compared with the randomized trial.
No takes yet. Share an insight, caveat, or question.
Ganyukov et al. (2015) conducted an editorial in High-risk percutaneous coronary intervention (n=555). Percutaneous left ventricular assist device (Impella 2.5) vs. Clinical trial patients (PROTECT II Impella arm) was evaluated on In-hospital mortality and adverse events.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: